Decreased neuraminidase activity is important for the adaptation of H5N1 influenza virus to human airway epithelium

Journal of Virology

Volumn 86, Issue 9, 2012, Pages 4724-4733

  Ilyushina, Natalia A ^a,b,e   Bovin, Nicolai V ^c   Webster, Robert G ^a,d  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b D I IVANOVSKY INSTITUTE OF VIROLOGY   (Russian Federation)

^c SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^e DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2,3 SIALYL RECEPTOR; HEMAGGLUTININ; OSELTAMIVIR; PERAMIVIR; RECEPTOR; UNCLASSIFIED DRUG; ZANAMIVIR;

ADAPTATION; ANIMAL CELL; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CELL STRAIN; CELL STRAIN HEK293; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; EPITHELIUM CELL; HUMAN; HUMAN CELL; INFLUENZA VIRUS A H5N1; MONITORING; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; RESPIRATORY EPITHELIUM; SEQUENCE ANALYSIS; VIRUS ATTACHMENT; VIRUS MUTATION; VIRUS REPLICATION; VIRUS STRAIN;

ADAPTATION, BIOLOGICAL; AMINO ACID SUBSTITUTION; ANIMALS; CELL LINE; DOGS; DRUG RESISTANCE, VIRAL; ENZYME ACTIVATION; ENZYME INHIBITORS; GENES, VIRAL; HEMAGGLUTININS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; KINETICS; MICROBIAL SENSITIVITY TESTS; MUTATION; NEURAMINIDASE; RECEPTORS, VIRUS; RESPIRATORY MUCOSA; RIBONUCLEOPROTEINS; SEQUENCE ANALYSIS, DNA; VIRUS REPLICATION;

AVES; ORTHOMYXOVIRIDAE;

EID: 84861302626     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06774-11     Document Type: Article

References (45)

1. Alexander WJ, et al. 2007. Nasal and pharyngeal concentrations of peramivir following intramuscular and intravenous administration in health volunteers, poster A-1410. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
2. Aytay S, Schulze IT. 1991. Single amino acid substitutions in the hemagglutinin can alter the host range and receptor binding properties of H1 strains of influenza A virus. J. Virol. 65:3022-3028.
3. Beigel JH, et al. 2005. Avian influenza A (H5N1) infection in humans. N. Engl. J. Med. 353:1374-1385.
4. Bovin NV, et al. 1993. Synthesis of polymeric neoglycoconjugates based on N-substituted polyacrylamides. Glycoconj. J. 10:142-151.
5. Cheung CL, et al. 2006. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J. Infect. Dis. 193:1626-1629.
6. Colman PM. 1994. Influenza virus neuraminidse: structure, antibodies, and inhibitors. Protein Sci. 3:1687-1696.
7. de Jong MD, et al. 2005. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353:2667-2672.
8. Deom CM, Caton AJ, Schulze IT. 1986. Host cell-mediated selection of a mutant influenza A virus that has lost a complex oligosaccharide from the tip of the hemagglutinin. Proc. Natl. Acad. Sci. USA 83:3771-3775.
9. Gambaryan AS, Matrosovich MN. 1992. A solid-phase enzyme-linked assay for influenza virus receptor-binding activity. J. Virol. Methods 39: 111-123.
10. Gu J, et al. 2007. H5N1 infection of the respiratory tract and beyond: a molecular pathology study. Lancet 370:1137-1145.
11. Hayden FG. 2001. Perspectives on antiviral use during pandemic influenza. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 356:1877-1884.
12. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster R. 2000. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc. Natl. Acad. Sci. U. S. A. 97:6108-6113.
13. Hoffmann E, Stech J, Guan Y, Webster RG, Perez DR. 2001. Universal primer set for the full-length amplification of all influenza A viruses. Arch. Virol. 146:2275-2289.
14. Hurt AC, et al. 2009. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res. 83:90-93.
15. Hurt AC, et al. 2007. Susceptibility of highly pathogenic A (H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res. 73:228-231.
16. Ilyushina NA, Govorkova EA, Gray TE, Bovin NV, Webster RG. 2008. A switch to human-like receptor specificity does not affect the neuraminidase-inhibitor susceptibility of influenza A (H5N1) viruses. PLoS Pathog. 4:e1000043.
17. Ilyushina NA, Seiler JP, Rehg JE, Webster RG, Govorkova EA. 2010. Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets. PLoS Pathog. 6:e1000933.
18. Kiso M, et al. 2011. Effect of an asparagines-to-serine mutation at position 294 in neuraminidase on the pathogenicity of highly pathogenic H5N1 influenza A virus. J. Virol. 85:4667-4672.
19. Le QM, et al. 2005. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437:1108.
20. Matrosovich MN, et al. 1993. Probing of the receptor-binding sites of the H1 and H3 influenza virus hemagglutinins by synthetic and natural sialosides. Virology 196:111-123.
21. Matrosovich MN, Matrosovich T, Carr J, Roberts NA, Klenk H-D. 2003. Overexpression of the α-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J. Virol. 77:8418-8425.
22. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk H-D. 2004. Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc. Natl. Acad. Sci. U. S. A. 101: 4620-4624.
23. McKimm-Breschkin J, et al. 2003. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob. Agents Chemother. 47:2264-2272.
24. McKimm-Breschkin JL. 2000. Resistance of influenza viruses to neuraminidase inhibitors-a review. Antiviral Res. 47:1-17.
25. McKimm-Breschkin JL, Selleck PW, Usman TB, Johnson MA. 2007. Reduced sensitivity of influenza A (H5N1) to osletamivir. Emerg. Infect. Dis. 13:1354-1357.
26. Memoli MJ, et al. 2011. Multidrug resistant 2009 pandemic influenza A(H1N1) viruses maintain fitness and transmissibility in ferrets. J. Infect. Dis. 203:348-357.
27. Monto AS. 2005. The threat of an avian influenza pandemic. N. Engl. J. Med. 352:323-325.
28. Moscona A. 2008. Medical management of influenza infection. Annu. Rev. Med. 59:397-413.
29. Moscona A. 2009. Global transmission of oseltamivir-resistant influenza. N. Engl. J. Med. 360:953-956.
30. Nobusawa E, et al. 1991. Comparison of complete amino acid sequences and receptor-binding properties among 13 serotypes of hemagglutinins of influenza A viruses. Virology 182:475-485.
31. Ohuchi M, Ohuchi R, Feldmann A, Klenk H-D. 1997. Regulation of receptor binding affinity of influenza virus hemagglutinin by its carbohydrate moiety. J. Virol. 71:8377-8384.
32. Peiris JSM, de Jong MD, Guan Y. 2007. Avian influenza virus (H5N1): a threat to human health. J. Microb. Rev. 20:243-267.
33. Peng AW, Milleri S, Stein DS. 2000. Direct measurement of the antiinfluenza agent zanamivir in the respiratory tract following inhalation. Antimicrob. Agents Chemother. 44:1974-1976.
34. Potier M, Mameli L, Belisle M, Dallaire L, Melanxon SB. 1979. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferylalpha-D-N-acetylneuraminate) substrate. Anal. Biochem. 94:287-296.
35. Reed LJ, Muench H. 1938. A simple method for estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
36. Roche Pharmaceuticals. 2006. Tamiflu (oseltamivir carboxylate) capsules and for oral suspension. Package insert. Hoffmann-La Roche Inc., Nutley, NJ. http://www.tamiflu.com.
37. Russell RJ, et al. 2006. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443:45-49.
38. Salomon R, et al. 2006. The polymerase complex genes contribute to the high virulence of the human H5N1 influenza virus isolate A/Vietnam/ 1203/04. J. Exp. Med. 203:689-697.
39. Tisdale M. 2000. Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors. Rev. Med. Virol. 10:45-55.
40. Wagner R, Matrosovich MN, Klenk H-D. 2002. Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev. Med. Virol. 12:159-166.
41. Webster RG, Govorkova EA. 2006. H5N1 influenza-continuing evolution and spread. N. Engl. J. Med. 355:2174-2177.
42. Wiley DC, Skehel JJ. 1987. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu. Rev. Biochem. 56:365-394.
43. World Health Organization. 2011. Technical update: current evolution of avian influenza H5N1 viruses. World Health Organization, Geneva, Switzerland. http://www.who.int/influenza/human_animal _interface/tripartite_notes_H5N1.pdf.
44. Yen HL, et al. 2007. Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. J. Virol. 81:12418-12426.
45. Yuen KY, et al. 1998. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 351:467-471.